Wed. 22 May 2024, 7:34am ET
Benzinga
Biotech, News, Health Care, General
- This is the first compound in Zai's portfolio of internally developed drugs to advance into Phase 2, demonstrating Zai's global capabilities
- Based on a proof-of-concept study, ZL-1102 is the first topical biologic to show penetration of psoriatic skin resulting in a clinical response